title: Actin cytoskeletal rearrangement and dysfunction due to activation of the receptor for advanced glycation end products is inhibited by thymosin beta 4.
abstract: CONCLUSIONS
  Thymosin beta 4 (Tβ4 ) attenuates the vascular cellular toxicity induced by advanced glycation end products (AGEs) in human umbilical vein endothelial cells (HUVECs). Tβ4 reduces expression of both the receptor of AGEs (RAGE) and the filamentous actin (F-actin) to globular actin (G-actin) ratio. RAGE expression was regulated by actin cytoskeleton involved in Tβ4 . Tβ4 attenuates the vascular cellular toxicity induced by AGEs via remodelling of the actin cytoskeleton. AGEs attenuate vascular-like tube formation of HUVECs, which is reversed by Tβ4 via remodelling of the actin cytoskeleton.
  The receptor of advanced glycation end products (RAGE) is a cell-surface receptor that is a key factor in the pathogenesis of diabetic complications, including vascular disorders. Dysfunction of the actin cytoskeleton contributes to disruption of cell membrane repair in response to various type of endothelial cell damage. However, mechanism underlying RAGE remodelling of the actin cytoskeleton, by which globular actin (G-actin) forms to filamentous actin (F-actin), remains unclear. In this study we examined the role of thymosin beta 4 (Tβ4 ) - which binds to actin, blocks actin polymerization, and maintains the dynamic equilibrium between G-actin and F-actin in human umbilical vein endothelial cells (HUVECs) - in the response to RAGE. Tβ4 increased cell viability and decreased levels of reactive oxygen species in HUVECs incubated with AGEs. Tβ4 reduced the expression of RAGE, consistent with a down-regulation of the F-actin to G-actin ratio. The effect of remodelling of the actin cytoskeleton on RAGE expression was clarified by adding Phalloidin, which stabilizes F-actin. Moreover, small interfering RNA was used to determine whether intrinsic Tβ4 regulates RAGE expression in the actin cytoskeleton. The absence of intrinsic Tβ4 in HUVECs evoked actin cytoskeleton disorder and increased RAGE expression. These findings suggest that regulation of the actin cytoskeleton by Tβ4 plays a pivotal role in the RAGE response to AGEs.
authors: Department of Laboratory Animal Medicine, College of Veterinary Medicine, Chonbuk National University, Jeonju, Jeonbuk, 561-156, Republic of Korea.
authors: Sokho
authors: S
authors: Kim
authors: Jungkee
authors: J
authors: Kwon
mesh_terms: D008841:Actin Cytoskeleton / Q000187:drug effects* / Q000378:metabolism; D000199:Actins / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects* / Q000502:physiology; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D017382:Reactive Oxygen Species / Q000378:metabolism; D000067759:Receptor for Advanced Glycation End Products / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013947:Thymosin / Q000494:pharmacology*; D000099201:Thymosin beta(4)
chemical_list: D000199:Actins; D017382:Reactive Oxygen Species; D000067759:Receptor for Advanced Glycation End Products; D013947:Thymosin; D000099201:Thymosin beta(4)
references: Inflamm Res. 2011 Jan;60(1):3-10
references: 20845059
references: J Invest Dermatol. 1999 Sep;113(3):364-8
references: 10469335
references: Biochim Biophys Acta. 2014 Dec;1840(12):3452-9
references: 25230158
references: Nature. 2007 Jan 11;445(7124):177-82
references: 17108969
references: Diabetes Res Clin Pract. 2012 Apr;96(1):53-9
references: 22217673
references: Proc Natl Acad Sci U S A. 1977 Dec;74(12):5613-7
references: 341163
references: Ann N Y Acad Sci. 2012 Oct;1270:37-44
references: 23050815
references: Eur J Pharm Sci. 2012 Dec 18;47(5):875-83
references: 22985875
references: Circ Res. 2000 Jun 23;86(12):1198-202
references: 10864908
references: Clin Biochem. 2013 Jan;46(1-2):109-14
references: 23103709
references: Cell Motil Cytoskeleton. 1995;31(4):307-22
references: 7553917
references: Ann N Y Acad Sci. 2008 Apr;1126:46-52
references: 18448795
references: J Biol Chem. 1991 Mar 5;266(7):4029-32
references: 1999398
references: J Pathol. 2013 Jun;230(2):215-27
references: 22553146
references: Mediators Inflamm. 2010;2010:792393
references: 20634940
references: Am J Pathol. 1993 Dec;143(6):1699-712
references: 8256857
references: Cell. 2003 Feb 21;112(4):453-65
references: 12600310
references: In Vitro Cell Dev Biol. 1990 Feb;26(2):119-28
references: 1690206
references: Neurobiol Dis. 2012 Dec;48(3):546-55
references: 22922221
references: J Angiogenes Res. 2010 Sep 22;2:19
references: 20860825
references: Wien Med Wochenschr. 2010 Aug;160(15-16):414-8
references: 20812053
references: J Hypertens. 2010 Apr;28(4):780-8
references: 20186099
references: Eur J Clin Invest. 2010 Aug;40(8):742-55
references: 20649640
references: Circ Res. 2003 Apr 18;92(7):785-92
references: 12623881
references: Mol Cell Endocrinol. 2015 Feb 5;401:238-47
references: 25540921
references: Kidney Int. 1998 Nov;54(5):1637-51
references: 9844140
references: Exp Physiol. 2010 Sep;95(9):955-70
references: 20562294
references: J Cell Sci. 1995 Dec;108 ( Pt 12):3685-94
references: 8719875
references: Bosn J Basic Med Sci. 2010 May;10(2):84-8
references: 20507285
references: J Cardiovasc Pharmacol. 2010 Apr;55(4):300-7
references: 20422734
references: FASEB J. 2001 May;15(7):1118-31
references: 11344080
references: Diabetes. 2004 Feb;53(2):463-73
references: 14747299
references: J Proteome Res. 2011 Aug 5;10(8):3344-62
references: 21627321
references: J Am Coll Cardiol. 2000 Apr;35(5):1323-30
references: 10758976
references: Expert Opin Biol Ther. 2012 Jan;12(1):37-51
references: 22074294
references: Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S19-24
references: 18442180
references: FEBS Lett. 2010 Jan 4;584(1):61-6
references: 19944695
references: N Engl J Med. 1988 May 19;318(20):1315-21
references: 3283558
references: Cell Motil Cytoskeleton. 2006 Apr;63(4):222-30
references: 16496302
references: J Biol Chem. 2011 Oct 7;286(40):35061-70
references: 21844192